Tooth dentin defects reflect genetic disorders affecting bone mineralization

Bone

Volumn 50, Issue 4, 2012, Pages 989-997

  Opsahl Vital, S ^a,b   Gaucher, C ^a,b,c   Bardet, C ^a,g   Rowe, P S ^d   George, A ^e   Linglart, A ^b,f   Chaussain, C ^a,b  

^a and Plateforme d'Imagerie du Vivant   (France)

^b ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^c Hopital Albert Chenevier   (France)

^d UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^e UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^f HÔPITAL SAINT VINCENT DE PAUL   (France)

^g STANFORD UNIVERSITY   (United States)

Author keywords

Biomineralization; Bone; Hypophosphatemic rickets; Osteogenesis imperfecta; Tooth

Indexed keywords

ALFACALCIDOL; BISPHOSPHONIC ACID DERIVATIVE; CALCITRIOL; PHOSPHATE;

BONE MATRIX; BONE MINERALIZATION; CALCIUM METABOLISM; CLINICAL FEATURE; COL1A2 GENE; CRTAP GENE; DENTIN; DENTITION; ENDODONTICS; ENPP1 GENE; EXTRACELLULAR MATRIX; FAMILIAL HYPOPHOSPHATEMIC RICKETS; FGF23 GENE; GENE; GENE MUTATION; HUMAN; JAW OSTEONECROSIS; LEPRE1 GENE; NONHUMAN; ORTHODONTICS; OSTEOGENESIS IMPERFECTA; PATIENT COMPLIANCE; PHOSPHATE METABOLISM; PHOSPHATE REGULATING GENE WITH HOMOLOGIES TO ENDOPEPTIDAES ON THE X CHROMOSOME; PROTEIN DEGRADATION; REVIEW; TOOTH ABSCESS; TOOTH DEVELOPMENT; TOOTH DISEASE; TOOTH ERUPTION;

BONE AND BONES; CALCIFICATION, PHYSIOLOGIC; DENTIN; GENETIC DISEASES, INBORN; HUMANS; TOOTH;

EID: 84858081678     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2012.01.010     Document Type: Review

References (121)

1. Bonaventure J., Stanescu R., Stanescu V., Allain J.C., Muriel M.P., Ginisty D., et al. Type II collagen defect in two sibs with the Goldblatt syndrome, a chondrodysplasia with dentinogenesis imperfecta, and joint laxity. Am J Med Genet 1992, 44:738-753.
2. da Fonseca M.A. Dental findings in the Schimke immuno-osseous dysplasia. Am J Med Genet 2000, 93:158-160.
3. Wedgwood D.L., Curran J.B., Lavelle C.L., Trott J.R. Cranio-facial and dental anomalies in the Branchio-Skeleto-Genital (BSG) syndrome with suggestions for more appropriate nomenclature. Br J Oral Surg 1983, 21:94-102.
4. Kantaputra P.N. A newly recognized syndrome of skeletal dysplasia with opalescent and rootless teeth. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2001, 92:303-307.
5. Kantaputra P.N. Apparently new osteodysplastic and primordial short stature with severe microdontia, opalescent teeth, and rootless molars in two siblings. Am J Med Genet 2002, 111:420-428.
6. Byers P.H., Bonadio J.F., Cohn D.H., Starman B.J., Wenstrup R.J., Willing M.C. Osteogenesis imperfecta: the molecular basis of clinical heterogeneity. Ann N Y Acad Sci 1988, 543:117-128.
7. Wright J.T. The molecular etiologies and associated phenotypes of amelogenesis imperfecta. Am J Med Genet A 2006, 140:2547-2555.
8. Huang B., Sun Y., Maciejewska I., Qin D., Peng T., McIntyre B., et al. Distribution of SIBLING proteins in the organic and inorganic phases of rat dentin and bone. Eur J Oral Sci 2008, 116:104-112.
9. Embery G., Hall R., Waddington R., Septier D., Goldberg M. Proteoglycans in dentinogenesis. Crit Rev Oral Biol Med 2001, 12:331-349.
10. Qin C., Baba O., Butler W.T. Post-translational modifications of sibling proteins and their roles in osteogenesis and dentinogenesis. Crit Rev Oral Biol Med 2004, 15:126-136.
11. Traub W., Arad T., Weiner S. Origin of mineral crystal growth in collagen fibrils. Matrix 1992, 12:251-255.
12. He G., Gajjeraman S., Schultz D., Cookson D., Qin C., Butler W.T., et al. Spatially and temporally controlled biomineralization is facilitated by interaction between self-assembled dentin matrix protein 1 and calcium phosphate nuclei in solution. Biochemistry 2005, 44:16140-16148.
13. Sreenath T., Thyagarajan T., Hall B., Longenecker G., D'Souza R., Hong S., et al. Dentin sialophosphoprotein knockout mouse teeth display widened predentin zone and develop defective dentin mineralization similar to human dentinogenesis imperfecta type III. J Biol Chem 2003, 278:24874-24880.
14. Sun Y., Lu Y., Chen L., Gao T., D'Souza R., Feng J.Q., et al. DMP1 processing is essential to dentin and jaw formation. J Dent Res 2011, 90:619-624.
15. Sun Y., Prasad M., Gao T., Wang X., Zhu Q., D'Souza R., et al. Failure to process dentin matrix protein 1 (DMP1) into fragments leads to its loss of function in osteogenesis. J Biol Chem 2010, 285:31713-31722.
16. Alford A.I., Hankenson K.D. Matricellular proteins: extracellular modulators of bone development, remodeling, and regeneration. Bone 2006, 38:749-757.
17. Hunter G.K., Goldberg H.A. Modulation of crystal formation by bone phosphoproteins: role of glutamic acid-rich sequences in the nucleation of hydroxyapatite by bone sialoprotein. Biochem J 1994, 302(Pt 1):175-179.
18. Fisher L.W., Fedarko N.S. Six genes expressed in bones and teeth encode the current members of the SIBLING family of proteins. Connect Tissue Res 2003, 44(Suppl. 1):33-40.
19. 2+ store. J Biol Chem 2003, 278:17500-17508.
20. Boskey A.L., Boyan B.D., Schwartz Z. Matrix vesicles promote mineralization in a gelatin gel. Calcif Tissue Int 1997, 60:309-315.
21. Hoshi K., Ozawa H. Matrix vesicle calcification in bones of adult rats. Calcif Tissue Int 2000, 66:430-434.
22. Anderson H.C. Mechanism of mineral formation in bone. Lab Invest 1989, 60:320-330.
23. McKee M.D., Pedraza C.E., Kaartinen M.T. Osteopontin and wound healing in bone. Cells Tissues Organs 2011, 194:313-319.
24. Simon S., Smith A.J., Lumley P.J., Berdal A., Smith G., Finney S., et al. Molecular characterization of young and mature odontoblasts. Bone 2009, 45:693-703.
25. Goldberg M., Smith A.J. Cells and extracellular matrices of dentin and pulp: a biological basis for repair and tissue engineering. Crit Rev Oral Biol Med 2004, 15:13-27.
26. Dallas S.L., Bonewald L.F. Dynamics of the transition from osteoblast to osteocyte. Ann N Y Acad Sci 2010, 1192:437-443.
27. Albright F., Butler A.M., Bloomberg E. Rickets resistant to vitamin D. Am J Dis Child 1937, 54:529-547.
28. Winters R.W., Graham J.B., Williams T.F., Mc F.V., Burnett C.H. A genetic study of familial hypophosphatemia and vitamin D resistant rickets with a review of the literature. Medicine (Baltimore) 1958, 37:97-142.
29. A gene (PEX) with homologies to endopeptidases is mutated in patients with X-linked hypophosphatemic rickets. The HYP Consortium. Nat Genet 1995, 11:130-136.
30. Gaucher C., Walrant-Debray O., Nguyen T.M., Esterle L., Garabedian M., Jehan F. PHEX analysis in 118 pedigrees reveals new genetic clues in hypophosphatemic rickets. Hum Genet 2009, 125:401-411.
31. Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nat Genet 2000, 26:345-348.
32. Lorenz-Depiereux B., Bastepe M., Benet-Pages A., Amyere M., Wagenstaller J., Muller-Barth U., et al. DMP1 mutations in autosomal recessive hypophosphatemia implicate a bone matrix protein in the regulation of phosphate homeostasis. Nat Genet 2006, 38:1248-1250.
33. Bergwitz C., Roslin N.M., Tieder M., Loredo-Osti J.C., Bastepe M., Abu-Zahra H., et al. SLC34A3 mutations in patients with hereditary hypophosphatemic rickets with hypercalciuria predict a key role for the sodium-phosphate cotransporter NaPi-IIc in maintaining phosphate homeostasis. Am J Hum Genet 2006, 78:179-192.
34. Lorenz-Depiereux B., Benet-Pages A., Eckstein G., Tenenbaum-Rakover Y., Wagenstaller J., Tiosano D., et al. Hereditary hypophosphatemic rickets with hypercalciuria is caused by mutations in the sodium-phosphate cotransporter gene SLC34A3. Am J Hum Genet 2006, 78:193-201.
35. Levy-Litan V., Hershkovitz E., Avizov L., Leventhal N., Bercovich D., Chalifa-Caspi V., et al. Autosomal-recessive hypophosphatemic rickets is associated with an inactivation mutation in the ENPP1 gene. Am J Hum Genet 2010, 86:273-278.
36. Lorenz-Depiereux B., Schnabel D., Tiosano D., Hausler G., Strom T.M. Loss-of-function ENPP1 mutations cause both generalized arterial calcification of infancy and autosomal-recessive hypophosphatemic rickets. Am J Hum Genet 2010, 86:267-272.
37. Brownstein C.A., Adler F., Nelson-Williams C., Iijima J., Li P., Imura A., et al. A translocation causing increased alpha-klotho level results in hypophosphatemic rickets and hyperparathyroidism. Proc Natl Acad Sci U S A 2008, 105:3455-3460.
38. Ruchon A.F., Tenenhouse H.S., Marcinkiewicz M., Siegfried G., Aubin J.E., DesGroseillers L., et al. Developmental expression and tissue distribution of Phex protein: effect of the Hyp mutation and relationship to bone markers. J Bone Miner Res 2000, 15:1440-1450.
39. Thompson D.L., Sabbagh Y., Tenenhouse H.S., Roche P.C., Drezner M.K., Salisbury J.L., et al. Ontogeny of Phex/PHEX protein expression in mouse embryo and subcellular localization in osteoblasts. J Bone Miner Res 2002, 17:311-320.
40. Boileau G., Tenenhouse H.S., Desgroseillers L., Crine P. Characterization of PHEX endopeptidase catalytic activity: identification of parathyroid-hormone-related peptide107-139 as a substrate and osteocalcin, PPi and phosphate as inhibitors. Biochem J 2001, 355:707-713.
41. Addison W.N., Masica D.L., Gray J.J., McKee M.D. Phosphorylation-dependent inhibition of mineralization by osteopontin ASARM peptides is regulated by PHEX cleavage. J Bone Miner Res 2010, 25:695-705.
42. Addison W.N., Nakano Y., Loisel T., Crine P., McKee M.D. MEPE-ASARM peptides control extracellular matrix mineralization by binding to hydroxyapatite: an inhibition regulated by PHEX cleavage of ASARM. J Bone Miner Res 2008, 23:1638-1649.
43. Martin A., David V., Laurence J.S., Schwarz P.M., Lafer E.M., Hedge A.M., et al. Degradation of MEPE, DMP1, and release of SIBLING ASARM-peptides (minhibins): ASARM-peptide(s) are directly responsible for defective mineralization in HYP. Endocrinology 2008, 149:1757-1772.
44. Rowe P.S., Kumagai Y., Gutierrez G., Garrett I.R., Blacher R., Rosen D., et al. MEPE has the properties of an osteoblastic phosphatonin and minhibin. Bone 2004, 34:303-319.
45. Liu S., Rowe P.S., Vierthaler L., Zhou J., Quarles L.D. Phosphorylated acidic serine-aspartate-rich MEPE-associated motif peptide from matrix extracellular phosphoglycoprotein inhibits phosphate regulating gene with homologies to endopeptidases on the X-chromosome enzyme activity. J Endocrinol 2007, 192:261-267.
46. Bresler D., Bruder J., Mohnike K., Fraser W.D., Rowe P.S. Serum MEPE-ASARM-peptides are elevated in X-linked rickets (HYP): implications for phosphaturia and rickets. J Endocrinol 2004, 183:R1-R9.
47. Nakatani T., Ohnishi M., Razzaque M.S. Inactivation of klotho function induces hyperphosphatemia even in presence of high serum fibroblast growth factor 23 levels in a genetically engineered hypophosphatemic (Hyp) mouse model. FASEB J 2009, 23:3702-3711.
48. Eicher E.M., Southard J.L., Scriver C.R., Glorieux F.H. Hypophosphatemia: mouse model for human familial hypophosphatemic (vitamin D-resistant) rickets. Proc Natl Acad Sci U S A 1976, 73:4667-4671.
49. Lyon M.F., Scriver C.R., Baker L.R., Tenenhouse H.S., Kronick J., Mandla S. The Gy mutation: another cause of X-linked hypophosphatemia in mouse. Proc Natl Acad Sci U S A 1986, 83:4899-4903.
50. Liu S., Brown T.A., Zhou J., Xiao Z.S., Awad H., Guilak F., et al. Role of matrix extracellular phosphoglycoprotein in the pathogenesis of X-linked hypophosphatemia. J Am Soc Nephrol 2005, 16:1645-1653.
51. Yuan B., Takaiwa M., Clemens T.L., Feng J.Q., Kumar R., Rowe P.S., et al. Aberrant Phex function in osteoblasts and osteocytes alone underlies murine X-linked hypophosphatemia. J Clin Invest 2008, 118:722-734.
52. White K.E., Larsson T.E., Econs M.J. The roles of specific genes implicated as circulating factors involved in normal and disordered phosphate homeostasis: frizzled related protein-4, matrix extracellular phosphoglycoprotein, and fibroblast growth factor 23. Endocr Rev 2006, 27:221-241.
53. Souza M.A., Soares Junior L.A., Santos M.A., Vaisbich M.H. Dental abnormalities and oral health in patients with hypophosphatemic rickets. Clinics (Sao Paulo) 2010, 65:1023-1026.
54. Chaussain-Miller C., Sinding C., Wolikow M., Lasfargues J.J., Godeau G., Garabedian M. Dental abnormalities in patients with familial hypophosphatemic vitamin D-resistant rickets: prevention by early treatment with 1-hydroxyvitamin D. J Pediatr 2003, 142:324-331.
55. Chaussain-Miller C., Sinding C., Septier D., Wolikow M., Goldberg M., Garabedian M. Dentin structure in familial hypophosphatemic rickets: benefits of vitamin D and phosphate treatment. Oral Dis 2007, 13:482-489.
56. Boukpessi T., Gaucher C., Leger T., Salmon B., Le Faouder J., Willig C., et al. Abnormal presence of the matrix extracellular phosphoglycoprotein-derived acidic serine- and aspartate-rich motif peptide in human hypophosphatemic dentin. Am J Pathol 2010, 177:803-812.
57. Glorieux F.H., Marie P.J., Pettifor J.M., Delvin E.E. Bone response to phosphate salts, ergocalciferol, and calcitriol in hypophosphatemic vitamin D-resistant rickets. N Engl J Med 1980, 303:1023-1031.
58. Boukpessi T., Septier D., Bagga S., Garabedian M., Goldberg M., Chaussain-Miller C. Dentin alteration of deciduous teeth in human hypophosphatemic rickets. Calcif Tissue Int 2006, 79:294-300.
59. Douyere D., Joseph C., Gaucher C., Chaussain C., Courson F. Familial hypophosphatemic vitamin D-resistant rickets-prevention of spontaneous dental abscesses on primary teeth: a case report. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2009, 107:525-530.
60. Ahovuo-Saloranta A., Hiiri A., Nordblad A., Makela M., Worthington H.V. Pit and fissure sealants for preventing dental decay in the permanent teeth of children and adolescents. Cochrane Database Syst Rev 2008, CD001830.
61. Kawakami M., Takano-Yamamoto T. Orthodontic treatment of a patient with hypophosphatemic vitamin D-resistant rickets. ASDC J Dent Child 1997, 64:395-399.
62. Sillence D.O., Senn A., Danks D.M. Genetic heterogeneity in osteogenesis imperfecta. J Med Genet 1979, 16:101-116.
63. Rauch F., Glorieux F.H. Osteogenesis imperfecta. Lancet 2004, 363:1377-1385.
64. Cabral W.A., Chang W., Barnes A.M., Weis M., Scott M.A., Leikin S., et al. Prolyl 3-hydroxylase 1 deficiency causes a recessive metabolic bone disorder resembling lethal/severe osteogenesis imperfecta. Nat Genet 2007, 39:359-365.
65. Gajko-Galicka A. Mutations in type I collagen genes resulting in osteogenesis imperfecta in humans. Acta Biochim Pol 2002, 49:433-441.
66. Millington-Ward S., McMahon H.P., Farrar G.J. Emerging therapeutic approaches for osteogenesis imperfecta. Trends Mol Med 2005, 11:299-305.
67. Baldridge D., Schwarze U., Morello R., Lennington J., Bertin T.K., Pace J.M., et al. CRTAP and LEPRE1 mutations in recessive osteogenesis imperfecta. Hum Mutat 2008, 29:1435-1442.
68. Marini J.C., Cabral W.A., Barnes A.M. Null mutations in LEPRE1 and CRTAP cause severe recessive osteogenesis imperfecta. Cell Tissue Res 2010, 339:59-70.
69. Willaert A., Malfait F., Symoens S., Gevaert K., Kayserili H., Megarbane A., et al. Recessive osteogenesis imperfecta caused by LEPRE1 mutations: clinical documentation and identification of the splice form responsible for prolyl 3-hydroxylation. J Med Genet 2009, 46:233-241.
70. Becker J., Semler O., Gilissen C., Li Y., Bolz H.J., Giunta C., et al. Exome sequencing identifies truncating mutations in human SERPINF1 in autosomal-recessive osteogenesis imperfecta. Am J Hum Genet 2011, 88:362-371.
71. Roughley P.J., Rauch F., Glorieux F.H. Osteogenesis imperfecta-clinical and molecular diversity. Eur Cell Mater 2003, 5:41-47. discussion 7.
72. Schnieke A., Harbers K., Jaenisch R. Embryonic lethal mutation in mice induced by retrovirus insertion into the alpha 1(I) collagen gene. Nature 1983, 304:315-320.
73. Stacey A., Bateman J., Choi T., Mascara T., Cole W., Jaenisch R. Perinatal lethal osteogenesis imperfecta in transgenic mice bearing an engineered mutant pro-alpha 1(I) collagen gene. Nature 1988, 332:131-136.
74. Chipman S.D., Sweet H.O., McBride D.J., Davisson M.T., Marks S.C., Shuldiner A.R., et al. Defective pro alpha 2(I) collagen synthesis in a recessive mutation in mice: a model of human osteogenesis imperfecta. Proc Natl Acad Sci U S A 1993, 90:1701-1705.
75. Forlino A., Porter F.D., Lee E.J., Westphal H., Marini J.C. Use of the Cre/lox recombination system to develop a non-lethal knock-in murine model for osteogenesis imperfecta with an alpha1(I) G349C substitution. Variability in phenotype in BrtlIV mice. J Biol Chem 1999, 274:37923-37931.
76. Aubin I., Adams C.P., Opsahl S., Septier D., Bishop C.E., Auge N., et al. A deletion in the gene encoding sphingomyelin phosphodiesterase 3 (Smpd3) results in osteogenesis and dentinogenesis imperfecta in the mouse. Nat Genet 2005, 37:803-805.
77. Opsahl S., Septier D., Aubin I., Guenet J.L., Sreenath T., Kulkarni A., et al. Is the lingual forming part of the incisor a structural entity? Evidences from the fragilitas ossium (fro/fro) mouse mutation and the TGFbeta1 overexpressing transgenic strain. Arch Oral Biol 2005, 50:279-286.
78. Goldberg M., Opsahl S., Aubin I., Septier D., Chaussain-Miller C., Boskey A., et al. Sphingomyelin degradation is a key factor in dentin and bone mineralization: lessons from the fro/fro mouse. The chemistry and histochemistry of dentin lipids. J Dent Res 2008, 87:9-13.
79. Khavandgar Z., Poirier C., Clarke C.J., Li J., Wang N., McKee M.D., et al. A cell-autonomous requirement for neutral sphingomyelinase 2 in bone mineralization. J Cell Biol 2011, 194:277-289.
80. Smith R. Osteogenesis imperfecta, non-accidental injury, and temporary brittle bone disease. Arch Dis Child 1995, 72:169-171. discussion 71-6.
81. Engelbert R.H., Pruijs H.E., Beemer F.A., Helders P.J. Osteogenesis imperfecta in childhood: treatment strategies. Arch Phys Med Rehabil 1998, 79:1590-1594.
82. Shields E.D., Bixler D., el-Kafrawy A.M. A proposed classification for heritable human dentine defects with a description of a new entity. Arch Oral Biol 1973, 18:543-553.
83. Lund A.M., Jensen B.L., Nielsen L.A., Skovby F. Dental manifestations of osteogenesis imperfecta and abnormalities of collagen I metabolism. J Craniofac Genet Dev Biol 1998, 18:30-37.
84. Malmgren B., Norgren S. Dental aberrations in children and adolescents with osteogenesis imperfecta. Acta Odontol Scand 2002, 60:65-71.
85. Pallos D., Hart P.S., Cortelli J.R., Vian S., Wright J.T., Korkko J., et al. Novel COL1A1 mutation (G559C) [correction of G599C] associated with mild osteogenesis imperfecta and dentinogenesis imperfecta. Arch Oral Biol 2001, 46:459-470.
86. Luder H.U., van Waes H., Raghunath M., Steinmann B. Mild dental findings associated with severe osteogenesis imperfecta due to a point mutation in the alpha 2(I) collagen gene demonstrate different expression of the genetic defect in bone and teeth. J Craniofac Genet Dev Biol 1996, 16:156-163.
87. Lindau B.M., Dietz W., Hoyer I., Lundgren T., Storhaug K., Noren J.G. Morphology of dental enamel and dentine-enamel junction in osteogenesis imperfecta. Int J Paediatr Dent 1999, 9:13-21.
88. Majorana A., Bardellini E., Brunelli P.C., Lacaita M., Cazzolla A.P., Favia G. Dentinogenesis imperfecta in children with osteogenesis imperfecta: a clinical and ultrastructural study. Int J Paediatr Dent 2010, 20:112-118.
89. Witkop C.J. Hereditary defects of dentin. Dent Clin North Am 1975, 19:25-45.
90. Hall R.K., Maniere M.C., Palamara J., Hemmerle J. Odontoblast dysfunction in osteogenesis imperfecta: an LM, SEM, and ultrastructural study. Connect Tissue Res 2002, 43:401-405.
91. Lygidakis N.A., Smith R., Oulis C.J. Scanning electron microscopy of teeth in osteogenesis imperfecta type I. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1996, 81:567-572.
92. Malmgren B., Lindskog S. Assessment of dysplastic dentin in osteogenesis imperfecta and dentinogenesis imperfecta. Acta Odontol Scand 2003, 61:72-80.
93. Schwartz S., Tsipouras P. Oral findings in osteogenesis imperfecta. Oral Surg Oral Med Oral Pathol 1984, 57:161-167.
94. Freedus M.S., Schaaf N.G., Ziter W.D. Orthognathic surgery in osteogenesis imperfecta. J Oral Surg 1976, 34:830-834.
95. Libman R.H. Anesthetic considerations for the patient with osteogenesis imperfecta. Clin Orthop Relat Res 1981, 123-125.
96. Lund A.M., Muller J., Skovby F. Anthropometry of patients with osteogenesis imperfecta. Arch Dis Child 1999, 80:524-528.
97. Stenvik A., Larheim T.A., Storhaug K. Incisor and jaw relationship in 27 persons with osteogenesis imperfecta. Scand J Dent Res 1985, 93:56-60.
98. O'Connell A.C., Marini J.C. Evaluation of oral problems in an osteogenesis imperfecta population. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1999, 87:189-196.
99. Isshiki Y. Morphological studies on osteogenesis imperfecta, especially in teeth, dental arch and facial cranium. Bull Tokyo Dent Coll 1966, 7:31-49.
100. Ward L.M., Rauch F., Whyte M.P., D'Astous J., Gates P.E., Grogan D., et al. Alendronate for the treatment of pediatric osteogenesis imperfecta: a randomized placebo-controlled study. J Clin Endocrinol Metab 2011, 96:355-364.
101. Ward K.A., Adams J.E., Freemont T.J., Mughal M.Z. Can bisphosphonate treatment be stopped in a growing child with skeletal fragility?. Osteoporos Int 2007, 18:1137-1140.
102. Bachrach L.K., Ward L.M. Clinical review 1: bisphosphonate use in childhood osteoporosis. J Clin Endocrinol Metab 2009, 94:400-409.
103. Glorieux F.H., Bishop N.J., Plotkin H., Chabot G., Lanoue G., Travers R. Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N Engl J Med 1998, 339:947-952.
104. Urade M. Bisphosphonates and osteonecrosis of the jaws. Clin Calcium 2007, 17:241-248.
105. Malmgren B., Astrom E., Soderhall S. No osteonecrosis in jaws of young patients with osteogenesis imperfecta treated with bisphosphonates. J Oral Pathol Med 2008, 37:196-200.
106. Chahine C., Cheung M.S., Head T.W., Schwartz S., Glorieux F.H., Rauch F. Tooth extraction socket healing in pediatric patients treated with intravenous pamidronate. J Pediatr 2008, 153:719-720.
107. Schwartz S., Joseph C., Iera D., Vu D.D. Bisphosphonates, osteonecrosis, osteogenesis imperfecta and dental extractions: a case series. J Can Dent Assoc 2008, 74:537-542.
108. Migliorati C.A., Schubert M.M., Peterson D.E. Bisphosphonate osteonecrosis (BON): unanswered questions and research possibilities. Rev Recent Clin Trials 2009, 4:99-109.
109. Huber M.A. Osteogenesis imperfecta. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2007, 103:314-320.
110. Kamoun-Goldrat A., Ginisty D., Le Merrer M. Effects of bisphosphonates on tooth eruption in children with osteogenesis imperfecta. Eur J Oral Sci 2008, 116:195-198.
111. Hodgson B. More about bisphosphonates. J Am Dent Assoc 2009, 140:829-830. discussion 30.
112. Bradaschia-Correa V., Massa L.F., Arana-Chavez V.E. Effects of alendronate on tooth eruption and molar root formation in young growing rats. Cell Tissue Res 2007, 330:475-485.
113. Grier RLt, Wise G.E. Inhibition of tooth eruption in the rat by a bisphosphonate. J Dent Res 1998, 77:8-15.
114. Hiraga T., Ninomiya T., Hosoya A., Nakamura H. Administration of the bisphosphonate zoledronic acid during tooth development inhibits tooth eruption and formation and induces dental abnormalities in rats. Calcif Tissue Int 2010, 86:502-510.
115. Guideline on oral heath care/dental management of heritable dental development anomalies. Pediatr Dent 2008, 30:196-201.
116. Bouvier D., Leheis B., Duprez J.P., Bittar E., Coudert J.L. Dentinogenesis imperfecta: long-term rehabilitation in a child. J Dent Child (Chic) 2008, 75:192-196.
117. Bouvier D., Duprez J.P., Morrier J.J., Bois D. Strategies for rehabilitation in the treatment of dentinogenesis imperfecta in a child: a clinical report. J Prosthet Dent 1996, 75:238-241.
118. Sapir S., Shapira J. Dentinogenesis imperfecta: an early treatment strategy. Pediatr Dent 2001, 23:232-237.
119. Bidra A.S., Uribe F. Successful bleaching of teeth with dentinogenesis imperfecta discoloration: a case report. J Esthet Restor Dent 2011, 23:3-10.
120. Croll T.P., Sasa I.S. Carbamide peroxide bleaching of teeth with dentinogenesis imperfecta discoloration: report of a case. Quintessence Int 1995, 26:683-686.
121. Jehan F., Gaucher C., Nguyen T.M., Walrant-Debray O., Lahlou N., Sinding C., et al. Vitamin D receptor genotype in hypophosphatemic rickets as a predictor of growth and response to treatment. J Clin Endocrinol Metab 2008, 93:4672-4682.